Can Remdesivir be used to treat COVID-19 (coronavirus)?
Yes, remdesivir (Veklury, GS-5734) can be used to treat COVID-19, Veklury was the first FDA approved treatment for COVID-19 in the United States.
Remdesivir (Veklury) has FDA approval for the treatment of COVID-19 in adults and children from birth with a positive SARS-CoV-2 viral test:
- who weigh at least 1.5 kilograms (about 3.3 pounds) and are
- hospitalized, or
- not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Veklury is contraindicated in patients who are allergic to Veklury or any of its components.
What is Remdesivir?
- Remdesivir is an antiviral drug that blocks an enzyme that the virus uses to make copies of itself, so there is a decrease in the quantity of coronavirus in the body.
- Remdesivir has also been studied in treatment of the viruses that cause MERS, SARS-CoV and Ebola.
How does Remdesivir work on COVID-19?
- For the SARS-CoV-2 virus to make you sick it has to first infect your cells.
- Secondly the virus needs to make a lot of copies of itself, so it can spread around your body which causes the COVID-19 symptoms.
- For the virus to make copies of itself, it needs an enzyme called RdRp (RNA- dependent RNA polymerase) but the Remdesivir stops the RdRp from working properly, so the virus can’t make its copies.
- This stops the virus numbers from increasing and stops the infection getting worse.
What did the Veklury clinical trials show?
ACTT-1 was a randomized, double-blind, placebo-controlled trial comparing Veklury and placebo treatment for hospitalized COVID-19 patients.
Veklury significantly improved recovery time:
- By five days in the overall study population (10 days vs 15 days).
- By seven days in patients who required oxygen support at baseline (11 days vs 18 days).
The secondary endpoint in the ACTT-1 trial showed Veklury:
- Reduced disease progression in patients needing oxygen, so that less of these patients required to go on to mechanical ventilation or ECMO (extracorporeal membrane oxygenation) (13% vs 23%).
PINETREE was a Phase 3 randomized, double-blind, placebo-controlled trial. The trial evaluated the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression.
Veklury significantly reduced the risk of COVID-19 related hospitalization or all-cause death by:
- 87% by Day 28 (Veklury 0.7% vs placebo 5.3%)
Related questions
- What Drugs Prevent or Treat Serious COVID-19 Cases
- Can you have Covid without a fever?
- Which breathing techniques help with COVID-19?
Is Remdesivir an FDA approved COVID-19 medicine?
Yes, remdesivir (Veklury) is an FDA approved medicine for treatment of COVID-19 patients who:
- have had a positive SARS-CoV-2 viral test
- weigh at least 1.5 kilograms (about 3.3 pounds)
- are hospitalized,
- or not hospitalized but have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
References
- https://www.drugs.com/history/remdesivir.html
- https://www.sciencedirect.com/science/article/pii/S0924857920300832?via%3Dihub
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567817/
- https://www.nature.com/articles/s41422-020-0282-0
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s024lbl.pdf
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0978fa8-53ff-4ca2-82a7-567fd3e958ca#S2.1
Read next
Can you become immune to COVID-19?
Patients who recover from COVID-19 make antibodies to the virus that may impart immunity for at least 6 months; however, breakthrough infections do occur and may be more likely with newly circulating variants of the virus. Immunizing with the latest recommended COVID-19 vaccine can help to extend your immunity and prevent disease. Continue reading
Is obesity a major risk factor for Covid-19?
Obesity is a major risk factor for covid-19 and people who are obese are more likely than those who are not obese to contract Covid-19 at a younger age, develop severe Covid-19, require hospitalization, oxygen, mechanical ventilation, intubation, or admission into ICU, end up in hospital sooner, or die from Covid-19. Continue reading
COVID-19 vaccines and variants: What you should know
As of May 2025, the top 5 variants circulating in the U.S. are all lineages of the Omicron variant are: LP.8.1 (73%), XFC (10%), XEC (4%), LF.7.7.2 (3%), and LF.7 (2%), as estimated by the CDC on the COVID Data Tracker.
Continue readingSee also:
Related medical questions
- How effective is Lagevrio (molnupiravir) for COVID-19?
- Is Omicron worse than Delta?
- Should I wear a face mask to protect myself from COVID-19?
- COVID-19: Why is social distancing so important?
- Why do more men die from coronavirus?
- Can ivermectin be used to treat COVID-19?
- Can you take Ibuprofen if you have COVID-19 (coronavirus)?
- What antibiotics kill Covid-19 (coronavirus)?
- What is the difference between Spikevax and mNEXSPIKE?
- COVID-19: What are the Stages and Causes of Death?
- What's the difference between Bacteria and Viruses?
- Does Zinc protect you from Covid-19 or boost your immune system?
- How do I Treat Nasal Congestion with COVID-19?
- Does Losartan block COVID-19 Coronavirus Receptors?
- An Update: Is hydroxychloroquine effective for COVID-19?
- Does Paxlovid make you less contagious?
- Where can I buy an at-home test kit for COVID-19?
- Can you take Paxlovid twice if COVID rebounds?
- Does Tamiflu (oseltamivir) work on COVID-19?
- Can vitamin C prevent or treat COVID-19 (coronavirus)?
- Does Mucinex help with Covid?
- Should I take Paxlovid after a Positive COVID-19 Test?
- Can I take NyQuil with COVID or after the COVID vaccine?
- How long does COVID-19 last? and other COVID-19 FAQ
Drug information
Related support groups
- Veklury (2 questions, 3 members)
- Remdesivir (2 questions, 4 members)
- COVID-19 (104 questions, 91 members)
- Influenza (116 questions, 98 members)